Matches in Nanopublications for { ?s ?p "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP891569.RAqbeMoD_Z08OXMrqWZ2du78_dHi5Pfl00a-PT0vFdI-Y130_provenance.
- NP583040.RAmdJC4hHQSRsczVFtQA-igDc1eBVD3wW2JFJRHWysPsk130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP583040.RAmdJC4hHQSRsczVFtQA-igDc1eBVD3wW2JFJRHWysPsk130_provenance.
- NP302298.RAXfjLyghsRttrVEQXaQ7YB95CIxygpoxa9K_5Qdv9uVM130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP302298.RAXfjLyghsRttrVEQXaQ7YB95CIxygpoxa9K_5Qdv9uVM130_provenance.
- NP921462.RAb6kjNUClKkcfjj4RmpcGla4a4VXpflgcwqRkkykrAew130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921462.RAb6kjNUClKkcfjj4RmpcGla4a4VXpflgcwqRkkykrAew130_provenance.
- NP756961.RApJd5aZ0koWvibOSSozejZoxzUj0K26w_S8hovt4e3ig130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756961.RApJd5aZ0koWvibOSSozejZoxzUj0K26w_S8hovt4e3ig130_provenance.
- NP864975.RAZzpguvXa0vPpCKJS3-GYeFHMfJr9CknUBJ3bbjnfmYM130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP864975.RAZzpguvXa0vPpCKJS3-GYeFHMfJr9CknUBJ3bbjnfmYM130_provenance.
- NP870381.RAJSr05HSejmgD5XH-dLFe-GtdHp3VqagO_pt2iHI09WM130_assertion description "[In this paper, we present evidence that decitabine (DAC), a DNA methylation inhibitor that is currently used for the treatment of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and other malignant neoplasms, is capable of eliciting an anti-tumor cytotoxic T lymphocyte (CTL) response in mouse EL4 tumor model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP870381.RAJSr05HSejmgD5XH-dLFe-GtdHp3VqagO_pt2iHI09WM130_provenance.